摘要
目的评价柔肝化纤颗粒联合阿德福韦酯片治疗慢性乙型肝炎(CHB)肝纤维化的疗效。方法采用两中心、随机对照的研究设计,筛选武鸣县人民医院及广西中医药大学第一附属医院2005年9月～2012年9月住院和门诊的肝炎肝纤维化患者240例,按2∶1∶1比例将240例患者分为A组120例(服用柔肝化纤颗粒联合阿德福韦酯片)、B组60例(予阿德福韦酯片或联合大黄蟅虫丸)、C组60例(单独给予阿德福韦酯片),治疗前后观察临床症状、肝功能、肝纤4项、肝脏B超的变化。结果 A组总体疗效达90.0%,治疗后患者症状体征计分优于治疗前及同期C组治疗后(P<0.05或P<0.01);在改善肝脏炎症活动度(肝功能)、肝纤维化指标下降幅度(P<0.05);A组48周时脾厚度恢复正常,门脉内径明显缩小,与治疗前及C组比较,差异均有统计学意义(P<0.05)。结论柔肝化纤颗粒联合阿德福韦酯更有利于阻断或逆转纤维化的形成和发展。
Objective To assess the therapeutic effect of Rougan Huaxian Particle combined with Adefovir Dipivoxil in treating chronic hepatitis B with fibrosis.Methods 240 hepatic fibrosis patients with chronic liver diseases in Wuming County People＇s Hospital and the First Affiliated Hospital of Guangxi Medical University from September 2005 to September 2012 were included in this study,according to the proportion of 2：1：1,the patients were divided into 120 cases of group A（Adefovir Dipivoxil combined with Rougan Huaxian Particle） and 60 cases of group B（Adefovir Dip ivoxil combined with Dahuang Zhechong Pill） or 60 cases of group C（Adefovir Dipivoxil alone）,the clinical symptoms,the changes of liver function,liver fibrosis markers and ultrasound examination were observed before and after treat ment.Results The overall effect of group A was 90.0%,clinical symptoms in group A were improved significantly com pared to those in the group C（P 0.05 or P 0.01）;liver function indexes,liver fibrosis markers in group A were sig nificantly improved compared with group C and the group before treatment,the difference was significant（P 0.05）;before treatment,spleen returned to normal thickness,portal vein diameter in group A were significantly reduced more than group C,the differences were significant（P 0.05）.Conclusion Rougan Huaxian Particle combined with Adefovir Dipivoxil has more advantages for preventing or reversing the formation and development of liver fibrosis.
出处
《中国医药导报》
CAS
2013年第22期88-90,共3页
China Medical Herald
基金
广西壮族自治区卫生厅重点科研课题(编号:重200935)
广西壮族自治区教育厅科研项目(编号:200911MS139)
广西科技攻关项目(编号:桂科攻11107009-3-1)
关键词
柔肝化纤颗粒
阿德福韦酯
慢性乙型肝炎
肝纤维化
Rougan Huaxian Particle
Adefovir Dipivoxil
Chronic hepatitis B
Liver fibrosis
